1. Home
  2. BRLT vs NEUP Comparison

BRLT vs NEUP Comparison

Compare BRLT & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Brilliant Earth Group Inc.

BRLT

Brilliant Earth Group Inc.

HOLD

Current Price

$1.43

Market Cap

22.5M

ML Signal

HOLD

NEUP

Neuphoria Therapeutics Inc.

HOLD

Current Price

$5.10

Market Cap

23.8M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
BRLT
NEUP
Founded
2005
1996
Country
United States
United States
Employees
N/A
8
Industry
Consumer Specialties
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
22.5M
23.8M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
BRLT
NEUP
Price
$1.43
$5.10
Analyst Decision
Hold
Strong Buy
Analyst Count
4
2
Target Price
$1.70
$21.00
AVG Volume (30 Days)
37.9K
45.2K
Earning Date
05-06-2026
05-23-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$437,483,000.00
N/A
Revenue This Year
$6.72
N/A
Revenue Next Year
$4.95
N/A
P/E Ratio
N/A
N/A
Revenue Growth
3.63
N/A
52 Week Low
$1.21
$3.65
52 Week High
$3.10
$21.31

Technical Indicators

Market Signals
Indicator
BRLT
NEUP
Relative Strength Index (RSI) 58.31 64.99
Support Level $1.38 $3.85
Resistance Level $1.48 $5.18
Average True Range (ATR) 0.07 0.22
MACD 0.01 0.04
Stochastic Oscillator 72.73 81.18

Price Performance

Historical Comparison
BRLT
NEUP

About BRLT Brilliant Earth Group Inc.

Brilliant Earth Group Inc is an digitally native omnichannel jewelry company selling The company's products include rings, necklaces, earrings, and bracelets. Its collection of premium-quality diamond engagement and wedding rings, gemstone rings, and fine jewelry is conceptualized by in-house design studio. The company operates in one operating and reporting segment, the retail sale of diamonds, gemstones and jewelry.

About NEUP Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.

Share on Social Networks: